Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 53, 2023 - Issue 3
281
Views
1
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Clinical pharmacokinetics of cefixime: a systematic review

, , , , , , , & show all
Pages 149-162 | Received 04 Apr 2023, Accepted 19 May 2023, Published online: 01 Jun 2023

References

  • Abdullah A, Mutmainnah M, Wikantyasning ER. 2022. Cocrystals of cefixime with nicotinamide: improved solubility, dissolution, and permeability. Indonesian J Pharm. 33:395–401.
  • Asiri YA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, Al-Yamani MJ, Alsarra IA, Al-Balla SA. 2005. Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers. Int J Clin Pharmacol Ther. 43(10):499–504.
  • Barbee LA, Nayak SU, Blumer JL, Oʼriordan MA, Gray W, Zenilman JM, Golden MR, Griffiss JM. 2018. A phase 1 pharmacokinetic and safety study of extended-duration, high-dose cefixime for cephalosporin-resistant Neisseria gonorrhoeae in the pharynx. Sex Transm Dis. 45(10):677–683.
  • Barré J. 1989. Pharmacokinetic properties of cefixime. Presse Med. 18(32):1578–1582. fre.
  • Brittain DC, Scully BE, Hirose T, Neu HC. 1985. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther. 38(5):590–594.
  • Brogden RN, Campoli-Richards DM. 1989. Cefixime. Drugs. 38(4):524–550.
  • Carsenti-Etesse H, Farinotti R, Durant J, Roger PM, De Salvador F, Bernard E, Rouveix B, Dellamonica P. 1998. Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol. Eur J Drug Metab Pharmacokinet. 23(3):357–366.
  • Choi D-H, Burm J-P. 2007. Bioequivalence evaluation of two brands of cefixime 100 mg capsule (suprax and alpha-cefixime) in Korean healthy volunteers. Biomol Ther. 15(3):182–186.
  • Cooke A, Smith D, Booth A. 2012. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 22(10):1435–1443.
  • Danafar H. 2015. A quick and easy high performance liquid chromatography method for evaluation of cefixime in human plasma. Pharm Biomed Res. 1(4):29–39.
  • Danafar H, Hamidi M. 2016. Pharmacokinetics and bioequivalence study of two formulations of cefixime in healthy male volunteers. Iran J Pharm Sci. 12(4):1–14.
  • Deguchi T, Yasuda M, Yokoi S, Ishida K-I, Ito M, Ishihara S, Minamidate K, Harada Y, Tei K, Kojima K, et al. 2003. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 9(1):35–39.
  • Deng X, Allan-Blitz LT, Klausner JD. 2019. Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sex Health. 16(5):488–499. eng.
  • Dhib M, Moulin B, Leroy A, Hameau B, Godin M, Johannides R, Fillastre J. 1991. Relationship between renal function and disposition of oral cefixime. Eur J Clin Pharmacol. 41(6):579–583.
  • Dresser J, Wilby KJ. 2021. Safety of single-dose oral cefixime, intramuscular ceftriaxone, or intramuscular gentamicin for the treatment of gonorrhea: a systematic review and meta-analysis. Ann Pharmacother. 55(7):914–920.
  • Duverne C, Bouten A, Deslandes A, Westphal JF, Trouvin JH, Farinotti R, Carbon C. 1992. Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimicrob Agents Chemother. 36(11):2462–2467.
  • Ev??Ne E, Brault M, Manche M, Sibille M, Montay G, Vital Durand D. 2001. Bioequivalence study of two formulations (sachet and tablet) of cefixime after single oral doses of 200 mg in healthy male volunteers. Clin Drug Invest. 21(4):287–294.
  • Faulkner R, Bohaychuk W, Haynes J, Desjardins R, Yacobi A, Silber B. 1988. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 34(5):525–528.
  • Faulkner R, Bohaychuk W, Lanc R, Haynes J, Desjardins R, Yacobi A, Silber B. 1988. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 21(6):787–794.
  • Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM, al. e. 1987. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 6(10):963–970.
  • Faulkner RD, Bohaychuk W, Desjardins RE, Look ZM, Haynes JD, Weiss AI, Silber BM. 1987. Pharmacokinetics of cefixime after once‐a‐day and twice‐a‐day dosing to steady state. J Clin Pharmacol. 27(10):807–812.
  • Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM. 1989. Bioequivalency of oral suspension formulations of cefixime. Biopharm Drug Dispos. 10(2):205–211.
  • Faulkner RD, Sia LL, Look ZM, Barone JS, Forbes SJ, Weiss AI, Silber BM. 1988. Bioequivalency of solid oral dosage forms of cefixime. Int J Pharm. 43(1–2):53–58.
  • Fischer J, Ganellin CR. 2010. Analogue-based drug discovery. Chem Int Newsmag IUPAC. 32(4):12–15.
  • Guay D, Meatherall R, Harding G, Brown G. 1986. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 30(3):485–490.
  • Healy DP, Sahai JV, Sterling LP, Racht EM. 1989. Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. Antimicrob Agents Chemother. 33(11):1994–1997. eng.
  • Higgins J. 2011. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; [updated 2011 March]. www cochrane-handbook org.
  • Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343:d5928.
  • Ibraimi Q, Bajrami S, Zenuni A, Aliji A. 2022. Treatment of upper respiratory tract infections with third generation cefalosporine in preschool children. Int J Med Sci. 7(13–14):143–148.
  • Jabbar EG, Al-Tamimi DJJ, Al-Mahroos MIA, Al-Tamimi ZJJ, Ibraheem JJ. 2021. Pharmacokinetics and bioequivalence study of two formulations of cefixime suspension. J Adv Pharm Educ Res. 11(1):170–177.
  • Khadam MW, Ashraf MM, Naz U, Bukhari NI, Tahir IM, Asghar D. 2019. Disposition kinetics, renal clearance and urinary excretion of cefixime in adolescent Pakistani boys-DRUG ANALYSIS REPORT. J Pak Med Assoc. 69(3):367–372.
  • Khan A, Iqbal Z, Khan MI, Javed K, Khan A, Ahmad L, Shah Y, Nasir F. 2011. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 879(24):2423–2429.
  • Leggett NJ, Caravaggio C, Rybak MJ. 1990. Cefixime. DICP. 24(5):489–495.
  • Liu P, Müller M, Grant M, Obermann B, Derendorf H. 2005. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol. 45(5):564–569.
  • Liu X, Xie L, Gao J, Lai L, Liu G. 1997. Cefixime absorption kinetics after oral administration to humans. Eur J Drug Metab Pharmacokinet. 22(2):185–188.
  • Long HA, French DP, Brooks JM. 2020. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Method Med Health Sci. 1(1):31–42.
  • Mamzoridi K, Kasteridou N, Peonides A, Niopas I. 1996. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose. Pharmacol Toxicol. 78(6):417–420.
  • McLinn SE. 1987. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J. 6(10):997–1001.
  • Moher D, Liberati A, Tetzlaff J, Altman DG. 2010. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 8(5):336–341.
  • Montay G, Masala F, Le Roux Y, Le Liboux A, Uhlrich J, Chassard D, Thebault J, Roche G, Frydman A. 1991. Comparative bioavailability study of cefixime administered as tablets or aqueous solution. Drugs. 42(Suppl 4):6–9.
  • Nahata MC, Kohlbrenner VM, Barson WJ. 1993. Pharmacokinetics and cerebrospinal fluid concentrations of cefixime in infants and young children. Chemotherapy. 39(1):1–5.
  • Najjar TA, Alkharfy KM, Saad SY. 2009. Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. J Infect Chemother. 15(2):70–74.
  • Nakashima M, Kanamaru M, Noguchi H, Kajiho T. 1986. Pharmacokinetics of FK027 (cefixime) in healthy volunteers after intravenous injection. Japanese J Clin Pharmacol Ther. 17(3):559–568.
  • Nakashima M, Uematsu T, Takiguchi Y, Kanamaru M. 1987. Phase I study of cefixime, a new oral cephalosporin. J Clin Pharmacol. 27(5):425–431.
  • Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB. 1997. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy. 17(1):121–125.
  • Nord CE, Movin G, Stålberg D. 1988. Impact of cefixime on the normal intestinal microflora. Scand J Infect Dis. 20(5):547–552.
  • Patil S, Hajare AL, Krishnaprasad K. 2014. Open-label, randomized, crossover comparative bioavailability study of cefixime from two tablet formulations after single oral administration. Int J Basic Clin Pharmacol. 3(6):943.
  • Rubin K, Sullivan D, Sadhasivam S. 2009. Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children? Paediatr Anaesth. 19(2):92–96.
  • Sabri NA. 2021. Cefixime and management protocols for COVID-19 second wave. Does its accurate detection in human plasma make sense? Acta Sci Pharm Sci. 5:46–53.
  • Soliman ABE, Pawluk SA, Wilby KJ, Rachid O. 2022. The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies. Int J Clin Pharm. 44(4):894–903.
  • Stone JW, Linong G, Andrews JM, Wise R. 1989. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 23(2):221–228.
  • Subiakto Y, Rismawan H, Tuba S. 2022. Quantitative analysis of generic cefixime in healthy subjects using UPLC-MS/MS and its bioavailability and pharmacokinetics evaluation utilization. Res Sq. https://doi.org/10.21203/rs.3.rs-1876303/v1
  • Tanvir SB, Qasim SSB, Shariq A, Najeeb S, Shah AH. 2018. Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections. Int J Health Sci. 12(5):90–100.
  • Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, Huy NT. 2019. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 47:46.
  • Taylor MM, Kara EO, Araujo MAL, Silveira MF, Miranda AE, Branco Coelho IC, Bazzo ML, Mendes Pereira GF, Pereira Giozza S, Bermudez XPD, et al. 2020. Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra). BMC Infect Dis. 20(1):1–15.
  • Toyonaga Y. 1997. Pharmacokinetics of antibiotics in children. Acta Paediatr Jpn. 39(1):114–123.
  • Trenk D, Wagner F, Bechtold H, Nies B, Jähnchen E. 1990. Lack of effect of cefixime on the metabolism of vitamin K1. J Clin Pharmacol. 30(8):737–742.
  • Westphal JF, Jehl F, Schloegel M, Monteil H, Brogard JM. 1993. Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrob Agents Chemother. 37(7):1488–1491.
  • Yu RX, Yin Y, Wang GQ, Chen SC, Zheng BJ, Dai XQ, Han Y, Li Q, Zhang GY, Chen X. 2014. Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis. PLOS One. 9(1):e87849.
  • Zakeri-Milani P, Valizadeh H, Islambulchilar Z. 2008. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 58(02):97–100.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.